Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
humanized monoclonal antibody with possible applications as animmunosuppressive drug .
Etymologies
from Wiktionary, Creative Commons Attribution/Share-Alike License
Support
Help support Wordnik (and make this page ad-free) by adopting the word ocrelizumab.
Examples
-
The study is the first of four needed to win approval of the humanized monoclonal antibody ocrelizumab, which is similar to Genentech and Biogen Idec's Rituxan, from the Food and Drug Administration.
Los Angeles Business News - Local Los Angeles News | Los Angeles Business from bizjournals 2009
-
The drug, called ocrelizumab, was studied in a combination therapy with another drug, known as MXT, in a phase 3 trial with over 1,000 enrolled patients.
Jacksonville Business News - Local Jacksonville News | Jacksonville Business Journal 2009
-
The study is the first of four needed to win approval of the humanized monoclonal antibody ocrelizumab, which is similar to Genentech and Biogen Idec's Rituxan, from the Food and Drug Administration.
San Antonio Business News - Local San Antonio News | The San Antonio Business Journal 2009
-
The study is the first of four needed to win approval of the humanized monoclonal antibody ocrelizumab, which is similar to Genentech and Biogen Idec's Rituxan, from the Food and Drug Administration.
San Antonio Business News - Local San Antonio News | The San Antonio Business Journal 2009
-
"In light of the DSMB recommendations we have decided to suspend ocrelizumab treatment in the rheumatoid arthritis clinical development program."
Roche, Biogen Suffer Setback With Experimental Drug Goran Mijuk 2010
-
Shares of Roche, which have gained around 51% over the past twelve months, showed little reaction to the news as investors were expecting another trial setback for ocrelizumab.
Roche, Biogen Suffer Setback With Experimental Drug Goran Mijuk 2010
-
Roche Holding AG and Biogen Idec Inc. said Monday they suspended a rheumatoid arthritis program using drug candidate ocrelizumab because of safety concerns, further cutting the experimental drug's market potential.
Roche, Biogen Suffer Setback With Experimental Drug Goran Mijuk 2010
-
"In light of the DSMB recommendations we have decided to suspend ocrelizumab treatment in the rheumatoid arthritis clinical development program."
Roche, Biogen Suffer Setback With Experimental Drug Goran Mijuk 2010
-
Roche Holding AG and Biogen Idec Inc. said Monday they suspended a rheumatoid arthritis program using drug candidate ocrelizumab because of safety concerns, further cutting the experimental drug's market potential.
Roche, Biogen Suffer Setback With Experimental Drug Goran Mijuk 2010
-
Roche Holding AG and Biogen Idec Inc. said Monday they suspended a rheumatoid arthritis program using drug candidate ocrelizumab because of safety concerns, further cutting the experimental drug's market potential.
Roche, Biogen Suffer Setback With Experimental Drug Goran Mijuk 2010
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.